These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 21466356)

  • 1. Best practices in diagnostic immunohistochemistry: myoepithelial markers in breast pathology.
    Dewar R; Fadare O; Gilmore H; Gown AM
    Arch Pathol Lab Med; 2011 Apr; 135(4):422-9. PubMed ID: 21466356
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnostic utility of p75 neurotrophin receptor (p75NTR) as a marker of breast myoepithelial cells.
    Popnikolov NK; Cavone SM; Schultz PM; Garcia FU
    Mod Pathol; 2005 Dec; 18(12):1535-41. PubMed ID: 16258511
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunohistochemical distinction of invasive from noninvasive breast lesions: a comparative study of p63 versus calponin and smooth muscle myosin heavy chain.
    Werling RW; Hwang H; Yaziji H; Gown AM
    Am J Surg Pathol; 2003 Jan; 27(1):82-90. PubMed ID: 12502930
    [TBL] [Abstract][Full Text] [Related]  

  • 4. D2-40: an additional marker for myoepithelial cells of breast and the precaution in interpreting tumor lymphovascular invasion.
    Ren S; Abuel-Haija M; Khurana JS; Zhang X
    Int J Clin Exp Pathol; 2011 Jan; 4(2):175-82. PubMed ID: 21326813
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of immunohistochemistry in the differential diagnosis of breast lesions.
    Moriya T; Kozuka Y; Kanomata N; Tse GM; Tan PH
    Pathology; 2009 Jan; 41(1):68-76. PubMed ID: 19089742
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The usefulness of p63 as a marker of breast myoepithelial cells.
    Batistatou A; Stefanou D; Arkoumani E; Agnantis NJ
    In Vivo; 2003; 17(6):573-6. PubMed ID: 14758723
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phenotypic alterations in myoepithelial cells associated with benign sclerosing lesions of the breast.
    Hilson JB; Schnitt SJ; Collins LC
    Am J Surg Pathol; 2010 Jun; 34(6):896-900. PubMed ID: 20463570
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunohistochemistry for diagnosis and prognosis of breast cancer: a review.
    Bonacho T; Rodrigues F; Liberal J
    Biotech Histochem; 2020 Feb; 95(2):71-91. PubMed ID: 31502889
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Myoepithelial cells in lobular carcinoma in situ: distribution and immunophenotype.
    Wang Y; Jindal S; Martel M; Wu Y; Schedin P; Troxell M
    Hum Pathol; 2016 Sep; 55():126-34. PubMed ID: 27195907
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of immunohistochemistry in the diagnosis of problematic breast lesions.
    Lee AH
    J Clin Pathol; 2013 Jun; 66(6):471-7. PubMed ID: 23486609
    [TBL] [Abstract][Full Text] [Related]  

  • 11. D2-40 expression by breast myoepithelium: potential pitfalls in distinguishing intralymphatic carcinoma from in situ carcinoma.
    Rabban JT; Chen YY
    Hum Pathol; 2008 Feb; 39(2):175-83. PubMed ID: 18206495
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phenotypic alterations in myoepithelial cells of the breast in normal and pathologic conditions.
    Pusztaszeri M
    Am J Surg Pathol; 2010 Dec; 34(12):1886; author reply 1886-7. PubMed ID: 21107098
    [No Abstract]   [Full Text] [Related]  

  • 13. Phenotypic alterations in ductal carcinoma in situ-associated myoepithelial cells: biologic and diagnostic implications.
    Hilson JB; Schnitt SJ; Collins LC
    Am J Surg Pathol; 2009 Feb; 33(2):227-32. PubMed ID: 18936688
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Myoepithelial cell differentiation markers in ductal carcinoma in situ progression.
    Russell TD; Jindal S; Agunbiade S; Gao D; Troxell M; Borges VF; Schedin P
    Am J Pathol; 2015 Nov; 185(11):3076-89. PubMed ID: 26343330
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diminished number or complete loss of myoepithelial cells associated with metaplastic and neoplastic apocrine lesions of the breast.
    Tramm T; Kim JY; Tavassoli FA
    Am J Surg Pathol; 2011 Feb; 35(2):202-11. PubMed ID: 21263240
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metaplastic breast carcinomas: are they of myoepithelial differentiation?: immunohistochemical profile of the sarcomatoid subtype using novel myoepithelial markers.
    Leibl S; Gogg-Kammerer M; Sommersacher A; Denk H; Moinfar F
    Am J Surg Pathol; 2005 Mar; 29(3):347-53. PubMed ID: 15725803
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD10 (Neutral Endopeptidase) Expression in Myoepithelial Cells of Salivary Neoplasms.
    Neves Cde O; Soares AB; Costa AF; de Araujo VC; Furuse C; Juliano PB; Altemani A
    Appl Immunohistochem Mol Morphol; 2010 Mar; 18(2):172-8. PubMed ID: 19752720
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunohistochemical staining characteristics of low-grade adenosquamous carcinoma of the breast.
    Kawaguchi K; Shin SJ
    Am J Surg Pathol; 2012 Jul; 36(7):1009-20. PubMed ID: 22446941
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intracystic papillary carcinomas of the breast: a reevaluation using a panel of myoepithelial cell markers.
    Collins LC; Carlo VP; Hwang H; Barry TS; Gown AM; Schnitt SJ
    Am J Surg Pathol; 2006 Aug; 30(8):1002-7. PubMed ID: 16861972
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A useful immunohistochemical approach to evaluate intraductal proliferative lesions of the breast and to predict their prognosis.
    Omi Y; Yamamoto T; Okamoto T; Obara T; Kobayashi M
    Histol Histopathol; 2011 Jan; 26(1):79-86. PubMed ID: 21117029
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.